Specify a stock or a cryptocurrency in the search bar to get a summary
LungLife AI Inc
LLAILungLife AI, Inc., a diagnostic company, researches and develops clinical diagnostic solutions for lung cancer with artificial intelligence (AI) technology in the United States and the People's Republic of China. The company engages in developing LungLB, a blood-based test to stratify cancerous and benign lung nodules identified by CT scan. The company was formerly known as Cynvenio Biosystems, Inc. and changed its name to LungLife AI, Inc. in May 2019. LungLife AI, Inc. was incorporated in 2009 and is based in Thousand Oaks, California. Address: 2545 West Hillcrest Drive, Thousand Oaks, CA, United States, 91320
Analytics
WallStreet Target Price
175.37 GBXP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures LLAI
Dividend Analytics LLAI
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History LLAI
Stock Valuation LLAI
Financials LLAI
Results | 2019 | Dynamics |